secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2023-01-11T23:59:59+00:00
Accession:  0001285550-23-000010
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q4 revenue $5.2M (+21%); FY2022 revenue $20.6M (+26%) missing guidance; FY2023 guide $25-27M
--------------------------------------------------------------------------------

- Preliminary Q4 2022 revenue $5.2M (+21% YoY); biologics/drug delivery $2.3M (+37%); functional neurosurgery $2.3M (+7%).
- Full year 2022 revenue $20.6M (+26% YoY), below guidance of $21-22M; cash burn $3.0M in Q4; cash $37.5M at year-end.
- FY2023 revenue guidance $25-27M (22-31% growth); backlog at highest level; CEO cites Q4 timing issues.
- Key upcoming milestones: PTC BLA submission for Upstaza, PRISM laser system commercial launch, 10 new centers, 8 FDA submissions.
- Added multiple new biologics/drug delivery partners, total >50; 11 new centers installed in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000128555023000010/0001285550-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000128555023000010/clpt-20230111.htm
  HTML page:      https://secwatch.observer/filing/0001285550-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer